StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie Neuroscience Portfolio — U.S. net revenues by Quarter

Neuroscience Portfolio — U.S. net revenues ($M) ($M)

QuarterlyAnnual

AbbVie Neuroscience Portfolio — U.S. net revenues: $2,771M in Q2 2026, up 18.8% from a year earlier. That is the highest of the 25 quarters on record here.

Latest, Q2 2026
2,771
Period ended Jun 30, 2026
Change on a year earlier
+18.8%
2,333 in Q2 2025
History
25 quarters
Since Q2 2020
Sources
25
Documents cited below

Where the Q2 2026 figure comes from

“|| Neuroscience | 2,771 | 457 | 3,228 | 18.8 | 29.9 | 20.3 | 25.7 | 19.8”

Source: Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗

Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNeuroscience Portfolio — U.S. net revenues ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20262,771+18.8%Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗
Q1 2026Mar 31, 20262,459+24.7%Form 8-K (abbv-20260331xexhibit991.htm, filed 2026-04-29) ↗
Q4 2025Dec 31, 20252,572+16.4%Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Q3 2025Sep 30, 20252,463+18.0%Form 8-K (abbv-20250930xexhibit991.htm, filed 2025-10-31) ↗
Q2 2025Jun 30, 20252,333+23.1%Form 8-K (abbv-20250630xexhibit991.htm, filed 2025-07-31) ↗
Q1 2025Mar 31, 20251,972+15.1%Form 8-K (abbv-20250331xexhibit991.htm, filed 2025-04-25) ↗
Q4 2024Dec 31, 20242,210+18.8%Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗
Q3 2024Sep 30, 20242,088+14.9%Form 8-K (abbv-20240930xexhibit991.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 20241,895+14.9%Form 8-K (abbv-20240630xexhibit991.htm, filed 2024-07-25) ↗
Q1 2024Mar 31, 20241,714+17.2%Form 8-K (abbv-20240331xexhibit991.htm, filed 2024-04-26) ↗
Q4 2023Dec 31, 20231,861+23.6%Form 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗
Q3 2023Sep 30, 20231,817+24.1%Form 8-K (abbv-20230930xexhibit991.htm, filed 2023-10-27) ↗
Q2 2023Jun 30, 20231,649+14.7%Form 8-K (abbv-20230630xexhibit991.htm, filed 2023-07-27) ↗
Q1 2023Mar 31, 20231,463+14.9%Form 8-K (abbv-20230331xexhibit991.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 20221,506+4.6%Form 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗
Q3 2022Sep 30, 20221,464+8.8%Form 8-K (abbv-20220930xexhibit991.htm, filed 2022-10-28) ↗

Breakdown

What makes up neuroscience Portfolio — U.S. net revenues

Cite this data

StockData. (2026). AbbVie Neuroscience Portfolio — U.S. net revenues ($M), quarterly Q2 2020–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/ta-neuro-us

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.